Neurolign Technologies is the world leader in neuro-functional monitoring and eye-tracking technology. The neurological health-tech company is on a mission to create a quantum shift in the clinical approach to neurodegenerative disease while simultaneously revolutionizing the way that consumers think and care for their ongoing brain health and wellness. Neurolign is driven by an overarching ethos of accessibility – making sophisticated eye-tracking equipment and brain health detection technology a viable option for a greater number of organizations and institutions, while also bringing the most widely applicable aspects of this pioneering technology into everyday homes. Founded in 2019 and headquartered in Toronto Canada, Neurolign is helmed by CEO and chairman Eugene Melnyk, a veteran of the health-tech and healthcare startup eco-system. Soon after their founding, Neurolign acquired Neuro Kinetics Inc., a long-time industry player, incorporating their technology into Neurolign solutions. Neurolign’s FDA-cleared I-Portal® devices have had more than more than 150 installations and are backed by over 30 years of research, experience, and development. Additional information on Neurolign is available at www.neurolign.com.